Standardized Evaluation of Subcutaneous Glucose Monitoring Systems Under Routine Environmental Conditions
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Device: Glucose Sensor
- Registration Number
- NCT02614768
- Lead Sponsor
- Medical University of Graz
- Brief Summary
The purpose of this study is to assess accuracy and reliability of the SPIDIMAN continuous glucose monitoring (CGM) sensor system with regard to values as measured by Super GL and compare these results with similar evaluations of the Medtronic MiniMed 640G system, the Abbott FreeStyle Libre Flash Sensor and the DexCom G4 Platinum Sensor in patients with type 1 Diabetes.
- Detailed Description
The study is a single-center open-label study in patients with type 1 diabetes treated with continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) therapy. The study will include a total of 12 subjects.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
- Informed consent obtained after being advised of the nature of the study
- Male or female aged ≥18 years
- Type 1 diabetes for at least 6 months according to the World Health Organization (WHO) definition
- Treatment with multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) for at least 3 months
- Body Mass Index (BMI) < 35 kg/m²
- Willing and able to wear 5 CGM devices for the duration of the study and undergo all study procedures.
- HbA1c ≤ 86 mmol/mol
- Any disease or condition which the investigator or treating physician feels would interfere with the trial or the safety of the subject
- Female of childbearing potential who is pregnant, breast-feeding or intend to become pregnant or is not using adequate contraceptive methods
- Any mental condition rendering the subject incapable of giving his consent
- Subject is using a medication that significantly impacts glucose metabolism (oral steroids) except if stable for at least the last three months and expected to remain stable for the study duration
- Subject may not use acetaminophen (paracetamol) while participating in the study
- Has severe medical or psychological condition(s) or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study.
- Subject is actively enrolled in another clinical trial
- Known adrenal gland problem, pancreatic tumour, or insulinoma
- Inability of the subject to comply with all study procedures
- Inability of the subject to understand the patient information.
- Subject donated blood in the last 3 months
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Glucose Sensor Glucose Sensor Continuous subcutaneous glucose monitoring using four different CGM systems in parallel will be performed throughout the study. Insulin therapy will be performed by the subjects themselves, as under daily life conditions. For the hypoglycaemia experiment an increased insulin bolus will be administered with meals (180% of the subject's calculated mealtime dose).
- Primary Outcome Measures
Name Time Method Percentage of Test-to-Reference Measurement Pairs With an Absolute Relative Difference (ARD) ≤15% 36 hours The primary outcome measure was overall sensor accuracy determined using ISO 15197:2013, which is percentage (%) of sensor values that are within ±0.8 mmol/L of the reference value at glucose concentrations \<5.6 mmol/L and within ±15% at glucose concentrations ≥5.6 mmol/L. The sensor values were obtained using three different glucose monitoring systems, i.e. Abbott, Dexcom and Medtronic, in patients with T1D over a 12-hour period in standardized conditions. The reference values were obtained by analysis of venous plasma glucose samples.
- Secondary Outcome Measures
Name Time Method